聚乙烯醇与碘油-博来霉素乳剂联合NBCA-碘油乳剂栓塞肾血管平滑肌脂肪瘤的前瞻性随机研究
该前瞻性随机研究纳入72例大(>4 cm)或有症状的肾血管平滑肌脂肪瘤患者,比较PVA与碘油-博来霉素乳剂联合NBCA-碘油乳剂行TAE的安全性和疗效。结果显示联合乳剂组在血尿缓解、 flank痛完全缓解、瘤体缩小、mRECIST完全缓解率及重复TAE率方面均优于PVA组,且无严重不良事件。
要点
- 联合乳剂组血尿缓解率100% vs PVA组80%(p=0.03)
- 联合乳剂组36个月以上瘤体平均缩小98.0% vs 85.7%(p=0.04)
- 联合乳剂组重复TAE率8.1% vs PVA组25.7%(p=0.04)
关键影像表现/征象
- 所有患者均实现血管造影可见动脉供血的完全闭塞。
临床应用与阅片要点
- 对于大(>4 cm)或有症状的肾AML,可优先考虑碘油-博来霉素乳剂联合NBCA-碘油乳剂进行TAE。
- 术后随访应关注血尿缓解、 flank痛缓解、瘤体缩小及mRECIST反应。
- PVA组重复TAE率较高,提示需更密切监测复发或未完全缓解病例。
局限性
- 单中心前瞻性研究,样本量有限(最终分析72例)。
- 随访时间较长但存在失访可能,原文未报告失访情况。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND. Consensus is lacking regarding optimal embolic agents for transcatheter arterial embolization (TAE) of renal angiomyolipomas (AMLs). OBJECTIVE. The purpose of our study was to compare the safety and efficacy of TAE with polyvinyl alcohol (PVA) and TAE with a combination of ethiodized oil (Lipiodol)-bleomycin emulsion and N-butyl cyanoacrylate (NBCA)-Lipiodol emulsion for the treatment of patients with large or symptomatic AMLs. METHODS. This prospective study enrolled patients referred for TAE of a large (> 4 cm) or symptomatic renal AML from July 2007 to December 2018. Patients were randomized to undergo TAE using PVA particles or a combination of Lipiodol-bleomycin emulsion and NBCA-Lipiodol emulsion. Patients underwent serial clinical follow-up visits and follow-up CT or MRI examinations after TAE. Outcomes were compared between groups. RESULTS. Seventy-eight patients were enrolled. After exclusions, the analysis included 72 patients (15 men, 57 women; mean age, 35.0 years; 51 patients with hematuria, 66 patients with flank pain): 35 patients were randomized to treatment by PVA and 37 were randomized to treatment by a combination of Lipiodol-bleomycin emulsion and NBCA-Lipiodol emulsion. Complete occlusion of all angiographically visible arterial supply was achieved in all patients. No major adverse event occurred in any patient. The mean follow-up after TAE was 77 ± 45 (SD) months (range, 37-180 months). The frequency of resolution of hematuria after initial TAE without recurrence was greater after treatment by Lipiodol-bleomycin emulsion and NBCA-Lipiodol emulsion than by PVA (100.0% vs 80.0%, respectively; p = .03). At 12-month follow-up, the frequency of complete resolution of flank pain was higher after treatment by Lipiodol-bleomycin emulsion and NBCA-Lipiodol emulsion than by PVA (100.0% vs 75.0%, p = .03). Mean reduction in AML volume at 36 months or longer after TAE versus at baseline was greater in patients treated by Lipiodol-bleomycin emulsion and NBCA-Lipiodol emulsion than in those treated by PVA (98.0% vs 85.7%, respectively; p = .04). The frequency of complete response by modified RECIST (mRECIST) criteria at 36 months or longer after TAE was greater in patients treated by Lipiodol-bleomycin emulsion and NBCA-Lipiodol emulsion than by PVA (94.6% vs 74.3%, p = .04). The rate of repeat TAE was higher among patients treated by PVA than among those treated by Lipiodol-bleomycin emulsion and NBCA-Lipiodol emulsion (25.7% vs 8.1%, p = .04). CONCLUSION. Superior outcomes after TAE of AML were achieved using Lipiodol-bleomycin emulsion and NBCA-Lipiodol emulsion than using PVA. CLINICAL IMPACT. TAE using a combination of Lipiodol-bleomycin emulsion and NBCA-Lipiodol emulsion is a safe and effective treatment option for large or symptomatic AMLs. TRIAL REGISTRATION. Chinese Clinical Trial Registry ChiCTR2100053296.
引用
- Wang, Duan, Zhang, et al. Comparison of Polyvinyl Alcohol Versus Combination of Lipiodol-Bleomycin Emulsion and NBCA-Lipiodol Emulsion for Renal Angiomyolipoma Embolization: A Prospective Randomized Study. AJR Am J Roentgenol. 2022. PMID: 36475816. doi:10.2214/AJR.22.28587
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。